Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

Compare

1,000 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

APLS Analyst Ratings

Moderate Buy

11 Buy

6 Hold

0 Sell

Based on 17 analysts giving stock ratings to

Apellis

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

APLS Stock 12 Month Forecast

Average Price Target

$33.33

▲(52.82% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Apellis Pharmaceuticals in the last 3 months. The average price target is $33.33 with a high forecast of $52.00 and a low forecast of $19.00. The average price target represents a 52.82% change from the last price of $21.81.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","53":"$53","25.25":"$25.3","34.5":"$34.5","43.75":"$43.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$19.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,25.25,34.5,43.75,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.12,27.18769230769231,29.255384615384617,31.323076923076925,33.39076923076923,35.45846153846154,37.526153846153846,39.59384615384616,41.66153846153846,43.72923076923077,45.79692307692308,47.86461538461539,49.93230769230769,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.12,25.751538461538463,26.383076923076924,27.014615384615386,27.646153846153847,28.27769230769231,28.90923076923077,29.54076923076923,30.17230769230769,30.803846153846152,31.435384615384613,32.066923076923075,32.69846153846154,{"y":33.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.12,24.64923076923077,24.17846153846154,23.70769230769231,23.236923076923077,22.76615384615385,22.295384615384616,21.824615384615385,21.353846153846156,20.883076923076924,20.412307692307692,19.941538461538464,19.470769230769232,{"y":19,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.91,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.01,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.87,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.17,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.47,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.12,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$52.00

Average Price Target$33.33

Lowest Price Target$19.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Eliana Merle

Barclays

$24

Hold

10.04%

Upside

Initiated

01/27/26

Apellis initiated with an Equal Weight at BarclaysApellis initiated with an Equal Weight at Barclays

Tazeen Ahmad

Bank of America Securities

$28

Buy

28.38%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Graig Suvannavejh

Mizuho Securities

$19

Hold

-12.88%

Downside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS), Ascendis Pharma (NASDAQ: ASND) and Abivax SA Sponsored ADR (NASDAQ: ABVX)

Derek Archila

Wells Fargo

$29→$26

Buy

19.21%

Upside

Reiterated

01/20/26

Wells Fargo Remains a Buy on Apellis Pharmaceuticals (APLS)

Lisa Walter

RBC Capital

$22

Hold

0.87%

Upside

Reiterated

01/20/26

RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/16/26

Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating

Annabel Samimy

Stifel Nicolaus

$48

Buy

120.08%

Upside

Reiterated

01/14/26

Apellis Pharmaceuticals (APLS) Gets a Buy from Stifel Nicolaus

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$22

Hold

0.87%

Upside

Reiterated

01/13/26

Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

Joseph Stringer

Needham

$29→$28

Buy

28.38%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (NASDAQ: APLS), Sarepta Therapeutics (NASDAQ: SRPT) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Yigal Nochomovitz

Citi

$117.8→$45

Buy

106.33%

Upside

Reiterated

01/13/26

Apellis Pharmaceuticals (APLS) Receives a Buy from Citi

Judah Frommer

Morgan Stanley

$25

Hold

14.63%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Douglas Tsao

H.C. Wainwright

$45

Buy

106.33%

Upside

Reiterated

01/12/26

Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target

Steven Seedhouse

Cantor Fitzgerald

$39→$35

Buy

60.48%

Upside

Reiterated

01/12/26

Apellis price target lowered to $35 from $39 at Cantor FitzgeraldApellis price target lowered to $35 from $39 at Cantor Fitzgerald

Phil Nadeau

TD Cowen

$45

Buy

106.33%

Upside

Reiterated

01/12/26

Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target

Anupam Rama

J.P. Morgan

$40→$36

Buy

65.06%

Upside

Reiterated

11/05/25

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Eliana Merle

Barclays

$24

Hold

10.04%

Upside

Initiated

01/27/26

Apellis initiated with an Equal Weight at BarclaysApellis initiated with an Equal Weight at Barclays

Tazeen Ahmad

Bank of America Securities

$28

Buy

28.38%

Upside

Reiterated

01/27/26

Bank of America Securities Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

Graig Suvannavejh

Mizuho Securities

$19

Hold

-12.88%

Downside

Reiterated

01/22/26

Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (NASDAQ: APLS), Ascendis Pharma (NASDAQ: ASND) and Abivax SA Sponsored ADR (NASDAQ: ABVX)

Derek Archila

Wells Fargo

$29→$26

Buy

19.21%

Upside

Reiterated

01/20/26

Wells Fargo Remains a Buy on Apellis Pharmaceuticals (APLS)

Lisa Walter

RBC Capital

$22

Hold

0.87%

Upside

Reiterated

01/20/26

RBC Capital Sticks to Its Hold Rating for Apellis Pharmaceuticals (APLS)

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/16/26

Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating

Annabel Samimy

Stifel Nicolaus

$48

Buy

120.08%

Upside

Reiterated

01/14/26

Apellis Pharmaceuticals (APLS) Gets a Buy from Stifel Nicolaus

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$22

Hold

0.87%

Upside

Reiterated

01/13/26

Wedbush Reaffirms Their Hold Rating on Apellis Pharmaceuticals (APLS)

Joseph Stringer

Needham

$29→$28

Buy

28.38%

Upside

Reiterated

01/13/26

Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (NASDAQ: APLS), Sarepta Therapeutics (NASDAQ: SRPT) and Mereo Biopharma Group Plc (NASDAQ: MREO)

Yigal Nochomovitz

Citi

$117.8→$45

Buy

106.33%

Upside

Reiterated

01/13/26

Apellis Pharmaceuticals (APLS) Receives a Buy from Citi

Judah Frommer

Morgan Stanley

$25

Hold

14.63%

Upside

Reiterated

01/13/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Apellis Pharmaceuticals (NASDAQ: APLS) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Douglas Tsao

H.C. Wainwright

$45

Buy

106.33%

Upside

Reiterated

01/12/26

Apellis Pharmaceuticals: Empaveli Momentum, Syfovre Franchise Durability, and Multi-Indication Expansion Support Reiterated Buy and $45 Target

Steven Seedhouse

Cantor Fitzgerald

$39→$35

Buy

60.48%

Upside

Reiterated

01/12/26

Apellis price target lowered to $35 from $39 at Cantor FitzgeraldApellis price target lowered to $35 from $39 at Cantor Fitzgerald

Phil Nadeau

TD Cowen

$45

Buy

106.33%

Upside

Reiterated

01/12/26

Apellis Pharmaceuticals: Syfovre and Empaveli Outperformance Plus Pipeline Upside Support Undervalued Buy Rating and $45 Target

Anupam Rama

J.P. Morgan

$40→$36

Buy

65.06%

Upside

Reiterated

11/05/25

J.P. Morgan Reaffirms Their Buy Rating on Apellis Pharmaceuticals (APLS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Apellis Pharmaceuticals

3 Months

xxx

Success Rate

22/35 ratings generated profit

Average Return

+2.19%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 62.86% of your transactions generating a profit, with an average return of +2.19% per trade.

1 Year

Yigal NochomovitzCiti

Success Rate

11/26 ratings generated profit

Average Return

-6.75%

reiterated a buy rating 16 days ago

Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 42.31% of your transactions generating a profit, with an average return of -6.75% per trade.

2 Years

xxx

Success Rate

15/29 ratings generated profit

Average Return

+1.30%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 51.72% of your transactions generating a profit, with an average return of +1.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

APLS Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, APLS has received 21 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. APLS average Analyst price target in the past 3 months is 33.33.

Each month's total comprises the sum of three months' worth of ratings.

APLS Financial Forecast

APLS Earnings Forecast

Next quarter’s earnings estimate for APLS is -$0.38 with a range of -$0.55 to -$0.16. The previous quarter’s EPS was $1.67. APLS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Sales Forecast

Next quarter’s sales forecast for APLS is $199.23M with a range of $184.82M to $232.45M. The previous quarter’s sales results were $458.58M. APLS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year APLS has Performed in-line its overall industry.

APLS Stock Forecast FAQ

What is APLS’s average 12-month price target, according to analysts?

Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is 33.33.

What is APLS’s upside potential, based on the analysts’ average price target?

Apellis Pharmaceuticals Inc has 52.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is APLS a Buy, Sell or Hold?

Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 11 buy ratings, 6 hold ratings and 0 sell ratings.

What is Apellis Pharmaceuticals Inc’s price target?

The average price target for Apellis Pharmaceuticals Inc is 33.33. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $52.00 ,the lowest forecast is $19.00. The average price target represents 52.82% Increase from the current price of $21.81.

What do analysts say about Apellis Pharmaceuticals Inc?

Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of APLS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Apellis Pharmaceuticals (APLS) Stock Forecast & Price Target

APLS Analyst Ratings

APLS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Apellis Pharmaceuticals

APLS Analyst Recommendation Trends

APLS Financial Forecast

APLS Earnings Forecast

APLS Sales Forecast

APLS Stock Forecast FAQ

Detailed List of Analyst Forecasts